Immunosuppressive treatment in multiple sclerosis

Journal of the Neurological Sciences

Volumn 223, Issue 1, 2004, Pages 1-11

  Weiner, Howard L ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Cyclophosphamide; Immunosuppression; Multiple sclerosis; Rescue therapy

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; BETA INTERFERON; BETA1A INTERFERON; CYCLOPHOSPHAMIDE; GLATIRAMER; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INTERFERON; INTERFERON BETA SERINE; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; MYCOPHENOLIC ACID; PREDNISONE; STEROID;

ALOPECIA; AMENORRHEA; BLADDER CANCER; BONE MARROW TRANSPLANTATION; CLINICAL TRIAL; CONFERENCE PAPER; DEGENERATIVE DISEASE; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG INDUCED CANCER; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EARLY MENOPAUSE; FOLLOW UP; GONAD DYSFUNCTION; HEMORRHAGIC CYSTITIS; HUMAN; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; INFERTILITY; INFLAMMATORY DISEASE; LUPUS ERYTHEMATOSUS NEPHRITIS; MAINTENANCE THERAPY; MALE INFERTILITY; MULTIPLE SCLEROSIS; NAUSEA; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; REMISSION; RHEUMATIC DISEASE; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 3142753454     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2004.04.013     Document Type: Conference Paper

References (92)

1. Martin R., McFarland H.F., McFarlin D.E. Immunological aspects of demyelinating diseases. Ann. Rev. Immunol. 10:1992;153-187
2. Hafler D.A., Weiner H.L. Antigen-specific immunosuppression: oral tolerance for the treatment of autoimmune disease. Chem. Immunol. 60:1995;126-149
3. Steinman L. Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system. Cell. 85(3):1996;299-302
4. Trapp B.D., et al. Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 338:1998;278-285
5. Lublin F.D., Reingold S.C. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology. 46:1996;907-911
6. Miller A., et al. Treatment of multiple sclerosis with copolymer-1 (Copaxone): implicating mechanisms of Th1 to Th2/Th3 immune-deviation. J. Neuroimmunol. 92:1998;113-121
7. Weiner H.L. Oral tolerance, an active immunologic process mediated by multiple mechanisms. J. Clin. Invest. 106(8):2000;935-937
8. Thompson A.J., et al. Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann. Neurol. 29:1991;53-62
9. Edan G., et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicenter study of active disease using MRI and clinical criteria. J. Neurol. Neurosurg. Psychiatry. 62:1997;112-118
10. Hartung H.P., Gonsette R.A.T.M.-S.G. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, randomized, observer-blind phase III trial: clinical results and three-year follow-up. Neurology. 52(Suppl 2):1999;290
11. European Study Group on interferon beta-1b in secondary progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet. 352(9139):1998;1491-1497
12. Goodkin D.E. The North American study of interferon beta-1b in secondary progressive multiple sclerosis. The 52nd Annual Meeting of the American Academy of Neurology. San Diego, California:2000
13. Aimard G., Girard P.F., Raveau J. Multiple sclerosis and the autoimmunization process. Treatment by antimitotics. Lyon Med. 215(6):1966;345-352
14. Hommes OWH, Results of a questionnaire on immunosuppressive treatment in multiple sclerosis, 2000.
15. Weiner H.L., Cohen J.A. Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects. Mult. Scler. 8(2):2002;142-154
16. Likosky W.H., Fireman B., Elmore R. Intense immunosuppression in chronic progressive multiple sclerosis: the Kaiser study. J. Neurol. Neurosurg. Psychiatry. 54:1991;1055-1060
17. The Canadian cooperative multiple sclerosis study group. The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. Lancet. 337(8739):1991;441-446
18. Langford C.A., et al. Use of cytotoxic agents and cyclosporine in the treatment of autoimmune disease: Part 2. Inflammatory bowel disease, systemic vasculitis, and therapeutic toxicity. Ann. Intern. Med. 129(1):1998;49-58
19. Notermans N.C., et al. Intermittent cyclophosphamide and prednisone treatment of polyneuropathy associated with monoclonal gammopathy of undetermined significance. Neurology. 47(5):1996;1227-1233
20. Good J.L., et al. Pulse cyclophosphamide therapy in chronic inflammatory demyelinating polyneuropathy. Neurology. 51(6):1998;1735-1738
21. Zimmerman R., et al. Advances in the treatment of lupus nephritis. Annu. Rev. Med. 52:2001;63-78
22. Gourley M., et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized controlled trial. Ann. Intern. Med. 125:1996;549-557
23. Wallace C.A., Sherry D.D. Trial of intravenous pulse cyclophosphamide and methylprednisolone in the treatment of severe systemic-onset juvenile rheumatoid arthritis. Arthritis Rheum. 40(10):1997;1852-1855
24. Schnabel A., Reuter M., Gross W.L. Intravenous pulse cyclophosphamide in the treatment of interstitial lung disease due to collagen vascular diseases. Arthritis Rheum. 41(7):1998;1215-1220
25. Martin R.H.R., McFarland H.F. Neurologic disorders: course and treatment. 1996;497-499 Academic Press, San Diego
26. Girard P.F., Pellet H. Therapeutique immuno-depressive en neurologie. Press Med. 75:1967;967-968
27. Millac P., Miller H. Cyclophosphamide in multiple sclerosis. Lancet. 1(7598):1969;783
28. Weiczorek V.L.W., Brodkorb W. Erfahrungen mit der immunosuppressive Behandlung der Multiplen Sklerose mit Cyclosphamid und Imuran. Disch. Ges. Wesen. 26:1971;1791-1794
29. Gopel W., Benkenstein H., Banzhaf M. Immunosuppressive therapy of multiple sclerosis using cyclophosphamide and imuran. Report on 57 cases. Dtsch. Gesundh. 27(41):1972;1955-1961
30. Cendrowski W. Combined therapeutic trial in multiple sclerosis: hydrocortisone hemisuccinate with cyclophosphamide or cytosine arabinoside. Acta Neurol. Belg. 73(4):1973;209-219
31. Drachman D.A., et al. Cyclophosphamide in exacerbations of multiple sclerosis. Therapeutic trial and a strategy for pilot drug studies. J. Neurol. Neurosurg. Psychiatry. 38(6):1975;592-597
32. Hommes O.R., Prick J.J.G., Lamers K.J.B. Treatment of the chronic progressive form of multiple sclerosis with a combination of cyclophosphamide and prednisone. Clin. Neurol. Neurosurg. 78:1975;59-73
33. Hommes O.R., Lamers K.J.B., Reekers P. Effect of intensive immunosuppression on the course of chronic progressive multiple sclerosis. J. Neurol. 223:1980;177-190
34. Hommes O.R., Lamers K.J.B., Reekers P. Prognostic factors in intensive immunosuppression on the course of chronic progressive multiple sclerosis. Bauer H.J., Poser S., Ritter G. Progress in multiple sclerosis research. 1980;396-400 Springer Verlag, Berlin
35. Theys P., et al. Short-term intensive cyclophosphamide treatment in multiple sclerosis. A retrospective controlled study. J. Neurol. 225(2):1981;119-133
36. Gonsette R., Demonty L., Delmotte P. Intensive immunosuppression with cyclophosphamide in multiple sclerosis: follow-up of 110 patients for 2-6 years. J. Neuroimmunol. 214:1977;173-181
37. Gonsette R.E., Demonty L., Delmotte P. Intensive immunosuppression with cyclophosphamide in remittent forms of multiple sclerosis. A follow up of 134 patients for 2-10 years. Bauer H.J., Poser S., Ritter G. Progress in Multiple Sclerosis Research. 1980;401-406 Bauer, HJ
38. Hauser S.L., et al. Immunosuppression and plasmapheresis in chronic progressive multiple sclerosis. Design of a clinical trial. Arch. Neurol. 40(11):1983;687-690
39. Carter J.L., et al. Immunosuppression with high-dose IV cyclophosphamide and ACTH in progressive multiple sclerosis: cumulative 6-year experience in 164 patients. Neurology. 38(2):1988;9-14
40. Weiner H.L., et al. Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group. Neurology. 43(5):1993;910-918
41. Goodkin D.E., et al. Cyclophosphamide in chronic progressive multiple sclerosis: maintenance vs. nonmaintenance therapy. Arch. Neurol. 44:1987;823-827
42. Hohol M.J., et al. Treatment of progressive multiple sclerosis with pulse cyclophosphamide/methylprednisolone: response to therapy is linked to the duration of progressive disease. Mult. Scler. 5(6):1999;403-409
43. Noseworthy J.E., Ebers G.C., Roberts R. Cyclophosphamide and MS - letter to the editor. Neurology. 44:1994;579-581
44. Weiner H.L., Orav E.J., Hafler D.A., Dawson D.M. Cyclophosphamide and MS-letter to the editor. Neruology. 44:1994;580-581
45. Noseworthy J.V., Vandervoort M.K., Penman M., Ebers G., Shumak K., Seland T.P., et al. Letters to the editor: cyclophosphamide and plasma exchange in multiple sclerosis. Lancet. 337:1991;579
46. Weiner H.L., Hauser S.L., Dawson D.M., Hafler D.A., Macklin G.A., Orav E.J. Letters to the editor: cyclophosphamide and plasma exchange in multiple sclerosis. Lancet. 337:1991;1033-1034
47. Noseworthy J.H., et al. An open-trial evaluation of mitoxantrone in the treatment of progressive MS. Neurology. 43:1993;1401-1406
48. Weinstock-Guttmann B., et al. Treatment of fulminant multiple sclerosis with intravenous cyclophosphamide. The Neurologist. 3:1997;178-185
49. Gobbini M.I., et al. Effect of open label pulse cyclophosphamide therapy on MRI measures of disease activity in five patients with refractory relapsing-remitting multiple sclerosis. J. Neuroimmunol. 99(1):1999;142-149
50. Khan O.A., et al. Effect of monthly intravenous cyclophosphamide in rapidly deteriorating multiple sclerosis patients resistant to conventional therapy. Mult. Scler. 7(3):2001;185-188
51. Patti F., et al. Combination of cyclophosphamide and interferon-beta halts progression in patients with rapidly transitional multiple sclerosis. J. Neurol. Neurosurg. Psychiatry. 71(3):2001;404-407
52. Khan O.A., et al. A prospective, open-label treatment trial to compare the effect of IFN beta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis. Eur. J. Neurol. 8(2):2001;141-148
53. Mancardi G.L., et al. Autologous hematopoietic stem cell transplantation suppresses Gd-enhanced MRI activity in MS. Neurology. 57(1):2001;62-68
54. Perini P., et al. Two years therapy of secondary progressive multiple sclerosis (SPMS) with pulse intravenous cyclophosphamide/methylprednisolone. Clinical and MRI data. Mult. Scler. 7:2001;S62
55. Perini P., Gallo P. Cyclophosphamide is effective in stabilizing rapidly deteriorating secondary progressive multiple sclerosis. J. Neurol. 250(7):2003;834-838
56. Zephir H., DeSeze J., Senechal O., Stojkovic T., Ferriby D., Delisse B., et al. Treatment of progressive multiple sclerosis with cyclophosphamide. Rev. Neurol. (Paris). 158(1):2002;65-69
57. Zephir H., DeSeze J., Duhamel A., Debouverie M., Hautecoeur P., Lebrun C., Malikova I., Pelletier J., Senechal O., Vermersch P. Treatment of progressive forms of multiple sclerosis by cyclophosphamide: a cohort study of 490 patients. J. Neurol. Sci. 218(1-2):2004;73-77
58. Boumpas D.T., et al. Risk for sustained amenorrhea in patients with systematic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann. Intern. Med. 119(5):1993;366-369
59. Slater C.A., et al. Preserving ovarian function in patients receiving cyclophosphamide. Lupus. 8(1):1999;3-10
60. Moore M.J. Clinical pharmacokinetics of cyclophosphamide. Clin. Pharmacokinet. 20(3):1991;194-208
61. Radis C.D., et al. Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year followup study. Arthritis Rheum. 38(8):1995;1120-1127
62. Talar-Williams C., et al. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann. Intern. Med. 124(5):1996;477-484
63. Myers L.W., et al. Cyclophosphamide "pulses" in chronic progressive multiple sclerosis. Arch. Neurol. 44:1987;828-832
64. Hafler D.A., Weiner H.L. Immunologic mechanisms and therapy in multiple sclerosis. Immunol. Rev. 144(3):1995;75-107
65. Hommes O.R., et al. Cyclophosphamide levels in serum and spinal fluid of multiple sclerosis patients treated with immunosuppression. J. Neurol. Sci. 58(2):1983;297-303
66. Bahr U., Schulten H.R., Hommes O.R., Aerts F. Determination of cyclophosphamide in urine, serum and cerebrospinal fluid of multiple sclerosis patients by field desorption mass spectrometry. Clin. Chim. Acta. 103:1980;183-192
67. Wender M., et al. Therapeutic trials of multiple sclerosis and intrathecal IgG production. Ital. J. Neurol. Sci. 7(2):1986;205-208
68. Lamers K.J., et al. The short-term effect of an immunosuppressive treatment on CSF myelin basic protein in chronic progressive multiple sclerosis. J. Neurol. Neurosurg. Psychiatry. 51(10):1988;1334-1337
69. Ten Berge R.J., van Walbeek H.K., Schellekens P.T. Evaluation of the immunosuppressive effects of cyclophosphamide in patients with multiple sclerosis. Clin. Exp. Immunol. 50(3):1982;495-502
70. Brinkman C.J., Nillesen W.M., Hommes O.R. T-cell subpopulations in blood and cerebrospinal fluid of multiple sclerosis patients: effect of cyclophosphamide. Clin. Immunol. Immunopathol. 29(3):1983;341-348
71. Moody D.J., et al. Administration of monthly-pulse cyclophosphamide in multiple sclerosis patients. Effects of long-term treatment on immunologic parameters. J. Neuroimmunol. 14(2):1987;161-173
72. Uitdehaag B.M., Nillesen W.M., Hommes O.R. Long-lasting effects of cyclophosphamide on lymphocytes in peripheral blood and spinal fluid. Acta Neurol. Scand. 79(1):1989;12-17
73. Hafler D.A., et al. Immunologic effects of cyclophosphamide/ACTH in patients with chronic progressive multiple sclerosis. J. Neuroimmunol. 32:1991;149-158
74. Strauss K., et al. The immune profile of multiple sclerosis: T-lymphocyte effects predominate over all other factors in cyclophosphamide-treated patients. J. Neuroimmunol. 63(2):1995;133-142
75. Smith D.R., et al. Immune deviation following pulse cyclophosphamide/ methylprednisolone treatment of multiple sclerosis: increased interleukin-4 production and associated eosinophilia. Ann. Neurol. 42(3):1997;313-318
76. Balashov K.E., et al. Increased IL-12 production in progressive multiple sclerosis: induction by activated CD4+ T-cells via CD40 ligand. Proc. Natl. Acad. Sci. U. S. A. 94:1997;599-603
77. Comabella M., et al. Cyclophosphamide treatment normalizes the increased IL-12 production in patients with chronic progressive MS and induces a Th2 cytokine switch. AAN Scientific Program. Neurology. 1998
78. van Boxel-Dezaire A.H., et al. Contrasting responses to interferon beta-1b treatment in relapsing-remitting multiple sclerosis: Does baseline interleukin-12p35 messenger RNA predict the efficacy of treatment? Ann. Neurol. 48(3):2000;313-322
79. Takashima H., et al. Pulse cyclophosphamide plus methylprednisolone induces myelin-antigen-specific IL-4-secreting T cells in multiple sclerosis patients. Clin. Immunol. Immunopathol. 88(1):1998;28-34
80. Padmanabhan B.K.A., Hanock W., Khoury S., Weiner H.L. Effect of cyclophosphamide pulse therapy on chemokine receptor expression in patients with multiple sclerosis. American Academy of Neurology 53rd Annual Meeting Program. Philadephia, PA: Neurology:2001
81. Karni A., et al. Cyclophosphamide modulates CD4(+) T cells into a T helper type 2 phenotype and reverses increased IFN-gamma production of CD8(+) T cells in secondary progressive multiple sclerosis. J. Neuroimmunol. 146(1-2):2004;189-198
82. Paterson P.Y., Drobish D.G. Cyclophosphamide: effect on experimental allergic encephalomyelitis in Lewis rats. Science. 165(889):1969;191-192
83. Harada M., Makino S. Promotion of spontaneous diabetes in non-obese diabetes-prone mice by cyclophosphamide. Diabetologia. 27(6):1984;604-606
84. Brown R.H., et al. Failure of immunosuppression with a ten- to 14-day course of high-dose intravenous cyclophosphamide to alter the progression of amyotrophic lateral sclerosis. Arch. Neurol. 43(4):1986;383-384
85. Balashov K.E., et al. CCR5(+) and CXCR3(+) T cells are increased in multiple sclerosis and their ligands MIP-1alpha and IP-10 are expressed in demyelinating brain lesions. Proc. Natl. Acad. Sci. U. S. A. 96(12):1999;6873-6878
86. Lucchinetti C., et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol. 47(6):2000;707-717
87. Smith D.W.-G., B., Cohen J., Guttman C., Olek M., Stuart W.H., et al. Design of randomized, blinded, MRI trial of pulse cyclophosphamide rescue therapy in B-IFN resistant active MS. American Academy of Neurology 53rd Annual Meeting. Philadelphia, PA: Neurology:2001
88. Calabresi P.A., et al. An open-label trial of combination therapy with interferon beta-1a and oral methotrexate in MS. Neurology. 58(2):2002;314-317
89. Lus G., et al. Azathioprine and interferon beta(1a) in relapsing-remitting multiple sclerosis patients: increasing efficacy of combined treatment. Eur. Neurol. 51(1):2004;15-20
90. Fernandez O., et al. Combination therapy with interferon beta-1b and azathioprine in secondary progressive multiple sclerosis. A two-year pilot study. J. Neurol. 249(8):2002;1058-1062
91. Portaccio E., et al. Safety and tolerability of cyclophosphamide 'pulses' in multiple sclerosis: a prospective study in a clinical cohort. Mult. Scler. 9(5):2003;446-450
92. Goodin D.S., et al. The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 61(10):2003;1332-1338